肺癌患者血清中miR-23a的表达及临床意义

Clinical significance of miR-23a expression in lung cancer

目的：探讨肺癌患者血清中miR-23a的表达情况及其与病例临床特征的关系。方法：提取63例肺癌患者和60例健康体检人血清中总mRNA，采用qRT-PCR方法检测miR-23a的相对表达量；统计分析miR-23a的表达与肺癌侵袭转移和患者耐药的关系。结果：与健康人相比，miR-23a在肺癌患者血清中表达增高（P〈0．01）；miR-23a在淋巴结转移患者血清中的表达量显著高于未转移患者（P〈0．01）；miR-23a在临床I～Ⅱ期肺癌患者血清中的表达低于Ⅲ～Ⅳ期患者（P〈0．05）；miR-23a在非小细胞肺癌患者中的表达高于小细胞肺癌患者（P〈0．05）；miR-23a的表达量在不同年龄、性别、吸烟及不同分化程度的患者中表达差异不显著（P〉0．05）。miR-23a的表达量随患者化疗次数的增多而表达增强。结论：血清miR-23a有可能作为肺癌患者转移及耐药判断的分子标志物。

Objective To investigate the expression of miR-23a in peripheral blood and analyze its correlation with the clinic-pathological features of patients with lung cancer. Methods The level of miR-23a in peripheral blood of 63 patients with lung cancer and 60 healthy persons was detected using real-time reverse transcription-polymerase chain reaction （RT-PCR）, The correlation between miR-23a level and the clinic- pathological features was analyzed. Results The expression level of miR-23a in peripheral blood of patients with lung cancer was significantly higher than that in the healthy persons （P 〈 0.01 ）.The level of miR-23a was associated with TNM stage （P 〈 0.05）, Lymphatic metastasis （P 〈 0.01） and the number of chemotherapy （P 〈 0.01 ）. Conclusion The miR-23a level in peripheral blood might be a molecular marker for the diagnosis and prognosis of patients with lung cancer.